Earlier, we reported the potency of a non-toxic small molecule Notch1 inhibitor, ASR490, a pyridine-2-carboxylic acid prodrug analog of Withaferin-A developed in our laboratories based on structure-activity relationship (SAR) studies on compounds generated by the modifications of Withaferin A core structure, in downregulating Notch1 expression and abrogating the growth of colon cancer cells (Tyagi et al., 2020). The gene discussed is NOTCH1; the disease is colonic neoplasm.